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he article shows the results of clinical and func-
tional changes in the myocardium in patients 
with chronic heart failure (CHF) after the per-
cutaneous coronary intervention (PCI). The study aimed 
to evaluate the results of clinical and functional changes 
in the left ventricular myocardium in patients with CHF 
after transluminal balloon angioplasty (TLBAP) of the 
coronary arteries with stenting of the coronary arteries 
during the observed period and to study the safety of sur-
gical intervention in these patients. During the year, 96 
patients with chronic heart disease (CHD) were observed 
in the age range from 40 to 70 years who had CHF I, 
IIA, IIB stages, from I to III functional class. All patients 
with clinical indications and coronary angiography (CAG) 
data were routinely performed TLBAP with stenting of 
a symptom-dependent coronary artery with appropriate 
medication. The study showed a statistically significant 
decrease in the functional class of CHF after percutane-
ous coronary intervention, followed by an improvement in 
the diastolic function (E/A) of the LV in the course of the 
observed period.
Keywords: coronary heart disease, chronic heart failure, 
percutaneous coronary intervention.
l artículo muestra los resultados de los cam-
bios clínicos y funcionales en el miocardio en 
pacientes con insuficiencia cardíaca crónica 
(ICC) después de la intervención coronaria percutánea 
(ICP). El objetivo del estudio fue evaluar los resultados de 
los cambios clínicos y funcionales en el miocardio ven-
tricular izquierdo en pacientes con ICC después de la an-
gioplastia transluminal con balón (TLBAP) de las arterias 
coronarias con colocación de stent de las arterias coronar-
ias durante el período observado y estudiar la seguridad 
de Intervención quirúrgica en estos pacientes. Durante el 
año, se observaron 96 pacientes con enfermedad cardíaca 
crónica (CHD) en el rango de edad de 40 a 70 años que 
tenían estadios de CHF I, IIA, IIB, de clase funcional I a 
III. Todos los pacientes con indicaciones clínicas y datos 
de angiografía coronaria (CAG) se realizaron de forma 
rutinaria TLBAP con colocación de stent de una arteria 
coronaria dependiente de los síntomas con la medicación 
adecuada. El estudio mostró una disminución estadística-
mente significativa en la clase funcional de ICC después 
de la intervención coronaria percutánea, seguida de una 
mejora en la función diastólica (E / A) del LV en el trans-
curso del período observado.
Palabras clave: Cardiopatía coronaria, insuficiencia 
cardíaca crónica, intervención coronaria percutánea.
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urrently, heart failure is one of the leading 
causes of morbidity, disability, and mortal-
ity in the Russian Federation, contrary to 
have achieved successful results in treatment. The statis-
tics show an increase in the number of CHF events not 
only in Russia but throughout the world. Prevalence of 
this disease in different regions of the Russian Federation 
varies in the range of 7 - 10% and is a major cause of 
death and ischemic origin remains symptom having a poor 
prognosis1. Leading etiological factors of CHF in the Rus-
sian Federation recognized as arterial hypertension (AH) 
(95.5%), Chronic heart disease (CHD) (69.7%), acute 
coronary syndrome (ACS) (15.3%), diabetes mellitus (DM) 
(15.9%). The combination of AH and CHD causes CHF in 
most patients1-3.
Taking into account the significant prevalence, severity, 
and malignancy of CHF development, significant expenses 
for treatment, one cannot ignore the issue of preventing 
the progression of the development of this syndrome. Re-
cently, attempts have been made to predict the develop-
ment of CHF in patients with IHD of different genesis4. In 
this case, the data of coronary angiography isn’t taken 
into account.
Treatment of patients with IHD, which is the second 
most important risk factor for CHF, is also very important 
in terms of treatment and progression of CHF5-7. For all 
non-pharmacological methods of treatment of CHF pa-
tients, the level of evidence is low and is based on the 
results of individual controlled studies8,9. In cases where 
conservative therapy does not make it possible to man-
age symptomatology in patients with IHD, it is advisable 
to perform myocardial revascularization 10,11. The literature 
data indicate contradictory results of the safety and ef-
ficacy of percutaneous coronary interventions in patients 
with CHD who have CHF. Several researchers empha-
size that patients with CHF are a group at high risk for 
coronary angioplasty10,12,13. Others note the superiority of 
percutaneous coronary intervention in patients with IHD 
who have severe LV systolic dysfunction concerning drug 
therapy14,15. Many studies have been devoted to the study 
of systolic and diastolic left ventricular (LV) myocardial dys-
function in patients with CHF of various genesis16. Nev-
ertheless, clinical-functional changes in LV myocardium 
after stenting of the coronary arteries have not been ad-
equately studied.
Aim: The study aimed to evaluate the results of clinic-
functional changes in LV myocardium after stenting of the 
coronary arteries in patients during the year. And to ana-
lyze and evaluate the effect of CHF on the effectiveness 
of percutaneous coronary interventions in patients with 
coronary heart disease. 
e examined 96 patients with 
IHD (stress angina, unstable an-
gina pectoris) aged 40-70 years 
(54.6 ± 0.74 yr), who underwent PCI of coronary arteries 
against the background of ongoing medical therapy. The 
following groups were identified: group 1 - 34 patients 
with CHF I, 2 group - 32 patients with CHF IIA and group 
3 - 30 patients with stage II CHF. Each of the groups was 
divided into I-III functional class (FC) CHF. The functional 
class of angina pectoris present in the history of CHF pa-
tients was II-III degree. The groups were representative of 
age and the presence of concomitant pathology.
To assess the dynamics of clinical and functional changes 
in the myocardium, the data of the study of patients were 
taken into account. Changes FC CHF were carried out on 
the rating scale of the clinical state (RSCS) and the results 
of the test of a 6-minute walk. In assessing the quality of 
life, the Minnesota Living with Heart Failure Questionnaire 
was developed specifically for patients with CHF. 
The criteria for inclusion in the study were: atherosclerotic 
lesions of coronary arteries (according to CAG stenosis 
≥70% of vessel diameter, clinical symptomatology, proven 
myocardial ischemia, exclusion criteria were: patients with 
acute coronary syndrome, patients with myocardial infarc-
tion (MI), and endovascular revascularization coronary 
arteries or CABG in the anamnesis, congenital and ac-
quired heart defects, cardiac rhythm disturbances, muscu-
loskeletal and lower limb disorders, of pulmonary system, 
marked reduction in body weight (body mass index (BMI) 
=35.0-39.9 kg/m2) and a massive obesity (IMT≥40 kg/m2). 
Coronary angiography and transluminal balloon angio-
plasty (TLBAP) with stenting were performed on the car-
diovascular system “Innova” by General Electric. During 
the surgical intervention, holo metallic stents and stents 
with medicinal coating Sirolimus were used. 
The study of the functional parameters of the heart was 
carried out using ultrasound in M- and B-modes on the 
Siemens Acuson X300 apparatus by a standard proce-
dure. The LVEF, the finite-diastolic size (FDS) and the finite-
systolic size (FSS) of the left ventricle, the finite-diastolic 
volume (FDV) and the LVEF, the thickness of the myocar-
dium of the posterior wall of the LV (TMPW), the thickness 
of the interventricular septum (TIVS), stroke volume of the 
LV (SV). LV diastole function was studied in pulsed Doppler 
mode with a mapping of the transmitral flow from the 
apical access of the four-chambered heart. The following 
parameters were measured from the transmittal diastolic 
flow curve: the maximum flow rate to the phase of early 
diastolic filling of the LV (E, m / s), the flow rate to the 
phase of late diastolic filling of the LV in atrial systolic (A, 
























and late diastolic filling of the LV (E / A). The time of iso-
volumetric relaxation of the myocardium of the LV (IVRT, 
ms) was measured as the interval from the moment of the 
termination of the aortic to the beginning of the transmit-
tal blood flow on the Doppler spectrum.
The endpoints of the study were analyzed in patients after 
coronary revascularization at the time of hospitalization, 3 
months, six months and one year later. Intraoperative and 
early complications (transient disturbances of rhythm and 
conduction, complications in the place of femoral access, 
acute and subacute stent thrombosis, coronary artery dis-
section and myocardial infarction) and late complications 
(myocardial infarction, late stent thrombosis, fatal out-
come) of endovascular revascularization were recorded. 
Statistical processing of the data was carried out by the 
principles of variation statistics using the software pack-
age “Statistika 6.0”. Tables are created using Microsoft 
Excel and Microsoft Word for Windows. The data in the 
tables are represented as M ± m, where M is the arithme-
tic mean, m is the mean error. The reliability of the differ-
ences in the compared average values was determined 
based on the Student’s test. The differences are reliable at 
the significance level (p <0.05).
he results of clinical and functional changes af-
ter stenting of the coronary arteries during the 
year in the observed patients are presented in 
Tables 1, 2 and 3. The indices of tables 1 and 2 show 
us that during the year of observation of patients with 
CHF I and CHF II stage positive dynamics of the indices of 
angina pectoris, FC of CHF, quality of life, increased exer-
cise tolerance after surgery during the study period. The 
results of the clinical examination, including the 6-minute 
walk test, confirmed that during the year, no functional 
group of CHFs changed in the direction of an increase 
in any patient of the control group. Controlled indices of 
central hemodynamics, systolic and diastolic LV function 
did not undergo significant changes. 
Thus, the average index of angina pectoris in the group 
of patients with Stage I CHF decreased from baseline 2.54 
± 0.09 to 1.67 ± 0.13, i.е. by 34.2% (p <0.001), in the 
patients with CHF IIA stage from 2.05 ± 0.08 to 0.86 ± 
0.11, i.e. by 57.6% (p <0.001) in the group of patients 
with CHF IIB stage from 2.25 ± 0.08 to 1.42 ± 0.11, i.е. 
by 37.8% (p <0.001). The value of FC CHF in the group of 
patients of Stage I decreased from the initial 1.76 ± 0.09 
to 1.31 ± 0.086, i.е. by 25.5% (p <0.05), in the IIA stage 
of the patients from 1.72 ± 0.091 to 1.31 ± 0.086, i.e. by 
23.8% (p <0.05). The difference between the values in 
both groups was statistically significant (p <0.05). In the 
group of patients with CHF IIB, no statistically significant 
differences were detected (p> 0.05). 
The baseline LVEF data demonstrate that most patients 
have CHF with a preserved LVEF. The initial ratio of the E/A 
flux rates indicates diastolic dysfunction in a hypertrophic 
type with a delayed relaxation. After endovascular inter-
ventions, there is a dynamic E/A towards normalization 
in all study groups, which after 12 months is statistically 
significant (p <0.05).
The frequency of complications in the operational and 
postoperative periods did not differ significantly in the 
groups of patients compared (Table 4), which corresponds 
to the data of modern literature14. In analyzing the ef-
ficacy and safety of coronary angioplasty with stenting in 
patients with CHF, depending on its stage and FC, the na-
ture and amount of affected coronary arteries, the degree 
of their stenosis, concomitant comorbid pathology and 
harmful habits, no differences were found. PCI is a safe 
and effective method of restoring antegrade blood flow in 
the coronary arteries in patients with CHD, characterized 
by low mortality, low incidence of acute myocardial infarc-
tion; absence, or decrease in the number of attacks of 
angina pectoris; absence of signs of myocardial ischemia 
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Table 1. The results of clinical and functional changes of the myocardium in patients with CHF I during the observed period (M±m)
Indicators Norm Hospital examination Examination after 3 months. after the therapy, PCI Examination after 6 months. Examination after 12 months.

























































р<0.05, р1>0.05 р2>0.05, 
p3<0.05






Note: p - reliability of differences between the indicators at the hospital stage and after 3 months;
p1 - reliability of differences between the indicators at 3 and 6 months after the operation;
p2 - reliability of differences between the indicators at 6 and 12 months;
p3 - reliability of differences between the indicators at the hospital stage and after 12 months.
Table 2. The results of clinical and functional changes of the myocardium in patients with CHF IIA during the observed period (M±m)
Indicators Norm Hospital examination Examination after 3 months. after the therapy, PCI Examination after 6 months. Examination after 12 months.



































































Table 3. The results of clinical and functional changes of the myocardium in patients with chronic heart failure IIB during the ob-
served period (M±m)
Indicators Norm Hospital examination Examination after 3 months. after the therapy, PCI Examination after 6 months. Examination after 12 months.
































































Table 4. Complications of percutaneous coronary interventions in the comparison groups
Complications and fate Comparison group № 1 (n = 34)
Comparison group № 
2 (n = 32)
Comparison group № 3 
(n = 30)
Groups 1‒2 Groups 1‒3 Groups 2‒3
p(t)
Intraoperative and early complications
Transient disturbances of rhythm 
and conduction 3 (8.8 %) 2 (6.2 %) 3 (10 %) >0.05 >0.05 >0.05
Complications in the place of 
femoral access 2 (5.9%) 1 (3.1 %) 2 (6.6 %) >0.05 >0.05 >0.05
Acute and subacute stent 
thrombosis – – – – – –
Coronary artery dissection 3 (8.8 %) 4 (12.5 %) 4 (13.3 %) >0.05 >0.05 >0.05
Myocardial infarction – 1 (3.1 %) – >0.05 >0.05 >0.05
Late complications
Myocardial infarction 1 (2.9 %) 1 (3.1 %) – >0.05 >0.05 >0.05
Late thrombosis of the stent – – – – – –
Fatal case – – – – – –
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evere, clinically pronounced and initial stages 
of CHF in patients with IHD are not signifi-
cant additional risks of complications during 
endovascular revascularization. Successfully performed 
angioplasty with stenting helps to reduce the severity of 
clinical symptoms and improve the diastolic function of 
the left ventricle with CHF I-III FC, I-IIA-IIB stages during 
the year after surgery.
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